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Summary. This communication reviews the evidence for the 
pivotal role of protein kinase C in ischemic myocardial pre- 
conditioning. It is believed that several intracellular signal- 
ling pathways via receptor-coupled phospholipase C and its 
"cross-talk" with phospholipase D converge to activation of 
protein kinase C isotypes which is followed by phosphoryla- 
tion of until now (a number of) unknown target proteins 
which produce the protective state of ischemic precondi- 
tioning. 
After briefly introducing the general biochemical proper- 
ties of protein kinase C, its isotypes and the limitations of 
the methodology used to investigate the role of protein kinase 
C, studies are discussed in which pharmacological inhibition 
and activation and (immunore)activity and/or isotypes mea- 
surements of protein kinase C isotypes were applied to assess 
the role of activation of protein kinase C in ischemic myocar- 
dial preconditioning. 
It is concluded that definitive proof for the involvement of 
protein kinase C in preconditioning requires future studies 
which must focus on the isotype(s) of protein kinase C that 
are activated, the duration of action, cellular translocation 
sites and the identity and stability (of covalently bound phos- 
phate) of phosphorylated substrate proteins. 
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Ischemic preconditioning is not an organ specific phe- 
nomenon, as it does not only occur in the heart [1,2], 
but also in kidney [3], liver [4] and skeletal muscle [5], 
while the brain is protected against he consequence 
of a new ischemic event at 24 hours after the precondi- 
tioning stimulus is applied [6]. Furthermore, brief 
ischemia in organs other than the heart may also limit 
irreversible damage produced by a subsequent coro- 
nary artery occlusion. Thus, in rats a 15-minute occlu- 
sion of the mesenteric artery with 10 minutes of reper- 
fusion prior to a 60-minute coronary artery occlusion 
limited myocardial infarct size by 40% [7]. Since gan- 
glion blockade abolished myocardial protection by 
mesenteric artery occlusion-reperfusion but not by 
brief coronary artery occlusion-reperfusion, the mech- 
anism of protection by brief ischemia-reperfusion in 
other organs appears to differ from that by brief myo- 
cardial ischemia-reperfusion [7]. 
Initially, ischemic preconditioning studies focussed 
on time characteristics and the search for extracellu- 
lar endogenous and exogenous factors that either 
mimicked or inhibited the phenomenon. It proved that 
protection occurred during two distinct episodes: a
classical preconditioning period (CPP) that lasted 2 to 
3 hours after the preconditioning stimulus was applied 
[1,2], and a second window of protection (SWOP) be- 
tween 24 and 72 hours [8-10]. The mechanisms of pro- 
tection for these two windows are most likely not the 
same. Rapidly produced endogenous factors may acti- 
vate intracellular pathways during CPP, while the 
slower process of induction of heat-shock proteins may 
be involved uring the SWOP. Initially, attention fo- 
cussed on activation of adenosine Al-receptors [11,12] 
or K~T P channel opening [13,14] as the mechanisms for 
protection during CPP. More recently activation of 
protein kinase C has received wide attention [15]. 
Prior to reviewing the role of protein kinase C, we 
review the current state of knowledge of the molecu- 
lar mechanism(s) of ischemic preconditioning, intro- 
duce the generally known biochemical properties of 
protein kinase C and discuss the limitations of the 
techniques used to investigate the potential role of 
protein kinase C. Finally, the evidence that activation 
of protein kinase C and the intracellular signalling 
pathways leading to its activation play a pivotal role 
in the mechanism ofischemic preconditioning is sum- 
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marized. However, not all studies support a role for 
protein kinase C in preconditioning and this issue re- 
mains therefore controversial t the present ime. 
Most studies on ischemic preconditioning used in- 
farct size as endpoint, but other endpoints uch as 
recovery of contractile function, and protection 
against reperfusion-induced ventricular arrhythmias 
have also been used. Because these other endpoints 
require different experimental conditions (i.e. shorter 
duration of the sustained occlusions) we have 
limited ourselves to studies which used infarct size 
as endpoint. For this same reason we have excluded 
studies on ischemic preconditioning in other 
organs. 
Current State of Knowledge 
of the Molecular Mechanism(s) 
of Ischemic Preconditioning 
Activation of receptors by exogenously administered 
stimuli such as adenosine [11,12], bradykinin [16,17], 
noradrenaline [18,19], acetylcholine [20,21], endo- 
thelin-1 [22] or opiates [23] mimic myocardial protec- 
tion by ischemic preconditioning. Intracellular signal- 
ling by these stimuli, via GTP-binding-protein-linked 
receptors and phospholipase C and possibly phospholi- 
pase D (see later) [24,25], leads to activation of one 
or more isotypes of the protein kinase C family which 
then phosphorylate putative target proteins [15,26]. 
Possible target proteins are those that regulate open- 
ing of K~T P channels [13,14,27], activate ecto-5'- 
nucleotidase [28] (during CPP) or modulate transcrip- 
tional regulation of the expression of heat shock 
proteins [29,30] (during SWOP). For instance, K~T P 
channels are opened when an ischemic preconditioning 
stimulus is applied, while blockade of g/~wp channels 
prevents ischemic preconditioning [13,14]. It is likely 
that modulation of K/~Tp channels in the mitochondria, 
sarcoplasmic reticulum or the nucleus are involved in 
the mechanism of protection as blockade of the action 
potential shortening by dofetilide does not abolish pro- 
tection by ischemic preconditioning [31]. Since protein 
kinase C can be activated via various receptors linked 
to phospholipase C- and possibly phospholipase D- 
mediated signalling pathways, these receptors may 
act synergistically [15]. Opening of K~T I, channels by 
pharmacological substances lowers the threshold for 
ischemic preconditioning [32], which is consistent with 
the hypothesis that K~T P channels are target proteins 
for protein kinase C. Kitakaze et al [28] reported that 
ischemic preconditioning increased ecto-5'-nucleo- 
tidase activity and that activation of protein kinase C 
increases ecto-5'-nucleotidase ctivity in isolated rat 
cardiomyocytes, supporting the candidacy of ecto-5'- 
nucleotidase as another target protein of protein ki- 
nase C. 
General Biochemical 
Properties o f  Protein Kinase C 
In general, the conformation of protein kinases con- 
sists of two regions which are connected by a region 
functioning as a hinge. The protein substrate fits into 
the groove between the two regions and interacts 
with a catalytic domain and cofactors interacting with 
the regulatory domain [33]. The specificity of protein 
kinases uch as cyclic AMP dependent protein kinase, 
Ca2÷-calmodulin dependent protein kinase (CaM-PK) 
and protein kinase C for their substrate proteins is 
determined by both the primary sequence of these 
proteins around their phosphorylation site and the ca- 
pacity of these sites to interact with the catalytic do- 
main of the protein kinase. Generally, protein kinases 
are inactivated by the interaction between a pseudo 
substrate region in the protein kinase's primary se- 
quence and the active site [33]. This restraint is re- 
moved during activation by changes in protein kinase 
conformation due to interaction of second messengers 
(e.g. cyclic AMP, 1,2-diacylglycerol (1,2-DAG) and 
Ca ~÷) with the protein kinase's regulatory sites and 
by competition between the protein substrates and 
the pseudo substrate site, all present at the N- 
terminal region of the primary structure of the protein 
kinases (Fig. 1). Indeed, activation of most protein 
Serine/Threonine (Ser/Thr) kinases is preceded by re- 
ceptor activation followed by synthesis or release of 
low-molecular-weight protein kinase effectors or sec- 
ond messengers. 
Protein kinases can be divided in several types. 
Protein kinase A is a cyclic AMP dependent protein- 
Ser/Thr kinase, while protein kinase C is a group of 
protein-Ser/Thr kinases which are phosphatidylserine 
(PtdSer-), 1,2-DAG- and/or Ca2+-dependent. Re- 
cently, protein kinase D was discovered in COS cells 
to be dependent on 1,2-DAG and phorbol esters, but 
information on this enzyme in myocardium is not yet 
available [35]. In myocardial cells protein kinase C 
regulates various processes, including myocardial con- 
traction, ion transport, energy metabolism, gene ex- 
pression and hypertrophic growth [25,36,37]. The role 
of protein kinase C in growth and proliferation has 
been implied by its identification as a high-affinity in- 
tracellular eceptor for tumor-promoting phorbol es- 
ters which directly activate most protein kinase C 
isotypes in a relatively unspecific manner. Phosphory- 
lation of target proteins by protein kinase C isotypes 
depends on their intracellular location at the time of 
action. This compartmentalization may be caused by 
the architecture and intracellular localization of anchor 
proteins e.g. the so-called receptors for activated C ki- 
nase (RACK) [38,39]. Therefore, after protein kinase C 
is activated it translocates to other cellular compart- 
ments uch as the sarcolemma where it exerts its prin- 
cipal action (Fig. 1). However, several other compart- 
ments such as mitochondria, myofibrils, sarcoplasmic 
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Fig. 1 Isotypes of protein kinase C ,  the functional domains in their primary structure, and receptor-coupled phospholipase C- 
mediated signal transduction leading to protein kinase C activation. The various protein kinase C isotypes share some sequence ho- 
mology and have all a common ATP-binding site (C3) and catalytic site (C4). Only protein kinase C - a, - P I ,  -& and - y have 
a Ca2+ binding site (C2) and 1,2-diacylglycerol (l,2-DAG)-binding site (C1). I n  the inactivated state the isotypes of protein kinase 
C are folded so that a n  endogenous 'pseudo substrate" region on the N-terminal part of the protein occupies the catalytic site (C- 
terminal part). When agonists (see text) bind to their specih receptors linked to phospholipase C in the cardiac sarcolemma, recep- 
tor activation is  followed by phospholipase C catalyzed hydrolysis of PtdIns(4,5)P2 to form inositol-l,4,5-trisphosphate 
(Ins(1,4,5)Py). Ins(1,4,5)Py releases Ca2+ from the Ins (1,4,5)Py receptor-sensitive Ca" storage sites in the cardiac sarcoplasmic re- 
ticulum. PtdIns(4,5)Pz hydrolysis also forms 1,2-diacylglycerol (1,2-DAG), which increases the a f in i ty  of some isotypes for Ca2+. 
When the intracellular free Ca2+ concentration increases, some isotypes become more tightly associated with membranes con- 
taining the negatively charged head groups of PtdSer, allowing 1,2-DAG to reach its binding site (C1) o n  the protein kinase C .  The 
1,2-DAG-protein kinase C complex approaches the membrane by placing the kinase in a pocket of negatively-charged head groups 
of PtdSer in which Ca2+ remains attracted. When this occurs, the conformation of protein kinase C changes, exposing the unoccu- 
pied catalytic site, thereby allowing the kinase to phosphorylate cellular proteins. There is  also evidence that specih  binding pro- 
teins (e.g. MARCKS and RACK)  determine the cellular translocation process of protein kinase C isotypes. The membrane-bound 
protein kinase C-DAG-fCa2+)-membrane complex only slowly dissociates and this pmperty is the basis for the commonly used 
"translocation assay" for assessment of PKC activation. Figure adapted from Zeisel et a1 [34], with permission of the F A S E B  
Journal. 
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reticulum and the perinuclear zone also possess specific 
receptor sites for protein kinase C isotypes [40]. 
Protein Kinase C Isotypes 
The protein kinase C family can be divided into three 
distinct subfamilies on basis of their structure and cat- 
alytic and regulatory properties (Fig. 1). Classical 
protein kinase C isotypes (cPKC's) such as protein 
kinase C-a, -[31, -~2 and -~/ are activated by Ca 2÷, 
PtdSer and 1,2-DAG or phorbol esters such as phor- 
bol-12-myristate-13-acetate (PMA). Novel protein ki- 
nase C isotypes (nPKC's) such as protein kinase C-g, 
-e, -0, -0 and -~ are Ca 2+ independent and only need 
PtdSer and 1,2-DAG (or PMA) to become activated. 
Atypical protein kinase C isotypes (aPKC's) are pro- 
tein kinase C-E, -t and -~ which are also Ca 2÷ indepen- 
dent and only require PtdSer to become activated 
(Fig. 1). At present, the still growing number of iso- 
types can be discriminated by immunoblot or immu- 
nohistofluorescence analysis. Most investigators use 
histone III-S as substrate and ~-~2P-labelled ATP as 
phosphate donor to measure protein kinase C activity, 
which reflects the activity of some of the isotypes 
present in the cellular fraction. Histone III-S is a poor 
substrate for some nPKC's (8, • and 0) compared to 
the other isotypes (~, ~1, [~2, ~/) [41]. Moreover, tech- 
niques such as hydroxylapatite high-pressure-liquid- 
chromatography can be used to determine the activity 
of protein kinase C isotypes after separation [42]. 
Measurement of the mRNA concentration using spe- 
cific cDNA probes on Northern blotting can also be 
used for the detection of protein kinase C isotypes 
[43], but mRNA levels offer only limited information 
because these do not always reflect he functional ac- 
tivities of the isotypes. 
In a preliminary study it was found that c~, ~, • 
and ~ are the most prominent isotypes in the rat heart 
[44]. Similar observations have been made in cultured 
neonatal rat cardiomyocytes [45] and adult rat cardio- 
myocytes [46]. However, in a more recent study in 
adult rat ventricular myocytes, protein kinase C-• was 
abundantly present and protein kinase C-a could not 
be detected [47,48], while in another study protein 
kinase C-a, -5, -•, -~, -0, -~, -~ and -L were detected 
in adult rat heart [49]. In the canine heart the pres- 
ence of protein kinase C-c~, -~1, -~2, -% -5, -•, -L, -0 
and -~ has been described [50]. Thus, the species and 
the type of assays determine the pattern of protein 
kinase C isotypes. Furthermore, the affinity and the 
specificity of the antibodies used to detect he protein 
kinase C isotypes determine the abundancy of detec- 
tion but not the absolute concentration ofthe isotype 
in vivo. In the pig, using rabbit polyclonal antibodies, 
we have demonstrated the presence of protein kinase 
C-c~ and -e, while the isotypes-5 and -~ were barely 
detectable. Other isotypes were not studied [51]. 
Myocardial homogenates donot only contain homoge- 
nized myocytes but also homogenized fibroblasts, 
smooth muscle cells and endothelial cells. Conse- 
quently, the protein kinase C isotypes of these cells 
in these homogenates are measured all together. So 
far, in only one study immunohistochemistry was used 
to detect he isotypes in situ [48]. In that study it was 
concluded that protein kinase C-5 is probably the most 
important isoform involved in preconditioning in the 
rat heart [48]. 
Protein Kinase C 
in Coupling Phospholipase C- 
to Phospholipase D-activation 
Endogenous ligands such as adenosine At, c~ 1- 
adrenergic- and muscarinic agonists, bradykinin, an- 
giotensin II, endothelin-1 or opiates timulate, via the 
receptor-G-protein coupled to phospholipase C, the in- 
tracellular signalling pathway [25,48,52-56]. Phospho- 
lipase C catalyzes hydrolysis of phosphatidy- 
linositol-4,5-biophosphate (P dlns (4,5)P 2) which leads 
to formation of the second messengers inositol-l,4, 
5°triophosphate (Ins(1,4,5)P~) and 1,2-DAG (Fig. 1) 
[25]. These messengers, directly or indirectly, acti- 
vate Ca2+-independent and/or Ca~+-dependent 
protein kinase C isotypes and calmodulin- 
dependent protein kinase (CaM-PK). The activated 
protein kinase C isotypes and/or CaM-PK phosphoryl- 
ate specific target proteins which may be responsible 
for CPP. Phospholipase D, another enzyme of 
which a stimulation leads to 1,2-DAG formation 
can be strongly stimulated by phorbol esters 
[36,45,51,57,58]. It uses phosphatidylcholine (PtdCho) 
as substrate and its activation leads initially to forma- 
tion of phosphatidic acid (PtdOH) and choline [59]. 
PtdOH is rapidly hydrolysed to 1,2-DAG and inor- 
ganic phosphate (Pi) by PtdOH hydrolase. The 1,2- 
DAG formed by phospholipase D potentially contrib- 
utes to activation of protein kinase C isotypes [51]. 
Stimuli such as noradrenaline, angiotensin II and en- 
dothelin-1 stimulate both phospholipase C and phos- 
pholipase D [45,58,60]. In fact, protein kinase C has 
been proposed to function as a switch which reduces 
the rate of PtdIns(4,5)P 2 hydrolysis catalyzed by phos- 
pholipase C and stimulates the rate of PtdCho hydro- 
lysis catalyzed by phospholipase D [57,58,59]. 
Through this "cross talk" mechanism between phos- 
pholipase C and D, the cardiomyocytes may be contin- 
uously supplied with 1,2-DAG after receptor stimula- 
tion, because the cellular concentration of PtdCho is 
about 100 times higher than that of PtdIns(4,5)P2. The 
continuous production of 1,2-DAG could be of im- 
portance for maintenance of activation of the protein 
kinase C isotypes involved in ischemic precondi- 
tioning. 
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Evidence fo r  a Role o f  Protein 
K inase C in Ischemic Precondit ioning 
Inhibition of protein kinase C (Table I) 
Selective inhibition of protein kinase C activation by 
administration of inhibitors prior to or after applying 
the cardioprotective stimulus is one approach to inves- 
tigate the role of protein kinase C in ischemic precon- 
ditioning. Depending on the inhibitor, protein kinase 
C function can be blocked at its catalytic or regulatory 
sites (Fig. 1). It is also possible to downregulate pro- 
tein kinase C activity by prolonged (1-2 days) stimula- 
tion with phorbol ester [61]. This last approach as 
not been used in ischemic preconditioning, but is of 
interest in view of the development of tolerance to 
ischemic preconditioning when a very large number 
of brief occlusion-reperfusion sequences are applied 
[62]. 
The most prominent drugs used to inhibit protein 
kinase activation or translocation are staurosporine 
[17,48,52,63], 1-(5-isoquinolinesulfonyl)-2-methylpiper- 
azine (H-7) [27,64], chelerythrine [53,65-67], calphos- 
tin-C [68], polymyxin B [17,52,55,56,64,66], bisindolyl- 
maleimide [28,69] and colchicine [63]. Staurosporine, 
H-7, and polymyxin B are non-specific inhibitors of 
protein kinase C compared to cyclic AMP-dependent 
protein kinase, CaM-PK or protein-Tyr kinases [70]. 
All non-selective inhibitors act on the catalytic domain 
of protein kinase C, which contains a high degree of 
sequence homology with other protein kinases. The 
more specific inhibitor calphostin-C [71] acts on the 
regulatory domain (Fig. 1). Chelerythrine, another 
specific inhibitor [67] interacts with the catalytic do- 
main but also competes with the classically used pro- 
tein substrates of protein kinase C [57]. Furthermore, 
polymyxin B directly blocks K~T P channels, one of the 
possible target proteins of protein kinase C and is 
therefore inappropriate to investigate the role of pro- 
tein kinase C in ischemic preconditioning [72,73]. 
Moreover, it is unknown whether protein kinase C 
inhibitors are equipotent for all enzyme isotypes. It 
is quite feasible that the degree of inhibition depends 
on both the isotype [60,74-76] and species. Table 1 
shows that polymyxin B [66], staurosporine [48] and 
chelerythrine [48] abolished the protective ffect in 
isolated rat hearts and calphostin-C [68] and cheler- 
ythrine [53] in the in vivo rat model. Polymyxin B 
[17,52,55,56] and staurosporine [17] abolished protec- 
tion in in vitro and polymyxin B [52], staurosporine 
[52,63], chelerythrine [67] and colchicine [63] in in vivo 
rabbit model. In dogs, the data are different as 
Przyklenk et al [64] observed that polymyxin B and 
H-7 did not abolish cardioprotection by ischemic pre- 
conditioning. In a preliminary study in pigs, stauro- 
sporine and bisindolylmaleimide limited infarct size 
[69]. These studies uggest adifferent role for protein 
kinase C in rats and rabbits than in dogs and pigs. 
The different results in rat, rabbit and pig could be 
related to species-dependent differences inmyocardial 
expression, in the task performed and the site of 
translocation of the various isotypes [38,39,48,64,77]. 
Moreover, the various isozymes might be activated 
differently by Ca 2÷, 1,2-DAG and free fatty acids 
[24,25,36,37]. 
Reviewing the studies using pharmacological block- 
ade one is tempted to conclude that the protein kinase 
C family is involved in the mechanism of ischemic pre- 
conditioning in rat and rabbit. However, none of the 
studies investigated whether blockade of protein ki- 
nase C actually occurred in the in vivo model. In vitro 
assays of enzyme activity will not provide conclusive 
answers also because these have to be performed in 
subcellular fractions in the absence of the inhibitor 
due to the isolation procedure and in the presence of 
optimal amounts of 1,2-DAG and/or Ca 2÷. The ideal 
experimental design would be to study the enzyme 
activity in vivo by measuring phosphorylation degrees 
of one or more of the unknown specific target proteins. 
Activation of protein kinase C (Table 2) 
Activation of protein kinase C by administration of 
phorbol esters, such as 12-O-tetradecanoyl phorbol- 
13-acetate (TPA) and PMA [27,66] or 1,2-DAG ana- 
logues such as 1-stearoyl-2-arachidonoyl glycerol 
(SAG) [48], 1,2-dioctanoyl sn-glycerol (DOG) [65] and 
oleyl acetylglycerol (OAG) [64] prior to a sustained 
coronary artery occlusion has been a second approach 
to investigate the role of protein kinase C in ischemic 
preconditioning. The advantage of using phorbol es- 
ters over 1,2-DAG as activating substances i that 
they are not metabolized and produce prolonged pro- 
tein kinase C activation. Protein kinase C transloca- 
tion takes place after phorbol ester (or the 1,2-DAG 
analog) is bound to the enzyme's regulatory domain 
whereby it obtains not only an increased affinity for 
acidic membrane phospholipids (PtdSer) but also an 
increased activity (Fig. 1). 
PMA and several 1,2-DAG analogs mimic precondi- 
tioning in the rat [53] and rabbit [52,63], but PMA 
failed to limit infarct size in pigs [69]. Przyklenk et 
al [64] measured protein kinase C translocation after 
administration ofPMA in dogs. Although these stud- 
ies lack information regarding activation (transloca- 
tion) of the isotype(s) in relation to the protective f- 
fect, the results with activators uggest a role for 
protein kinase C in ischemic preconditioning in rat and 
rabbit. Furthermore, the route of administration and 
the dose used may be different for the large animal 
studies and the in vitro and in vivo studies of small 
animals. For instance, Vogt et al [69] used intramyo- 
cardial administration ofPMA (1 ~LM) to activate pro- 
tein kinase C but failed to mimic the protective ffect 
of ischemic preconditioning. However, the dose could 
have been too high because Cohen et al [78] found that 
0.2 nM PMA was protective, while 2 nM PMA was 
damaging in the isolated rabbit heart. It is feasible 
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Table 1. Protein kinase C inhibitors and protection by ischemic preconditioning. 
Prolonged- 
CP-Stimulus Ischemia Evaluation 
Model Species x(I + R)(min) I(R)(min) Protein kinase C inhibitor (ISL/FR) Result Reference 
Isolated 
heart 
In Vivo 
Rat 3x(5I + 5R) 30I(120R) Polymyxin B, before CP-stim ISL Abolishes [66] 
3x(5I + 5R) 30I(120R) Chelerythrine, before CP-stim ISL Abolishes 
lx(2I + 10R) 20I(40R) Staurosporine, before CP-stim FR Abolishes [48] 
Phenylephrine + 10R 20I(40R) Staurosporine, before CP-stim FR Abolishes 
lx(2I + 10R) 20I(40R) Chelerythrine, before CP-stim FR Abolishes 
Phenylephrine + 10R 20I(40R) Chelerythrine, before CP-stim FR Abolishes 
Rabbit lx(5I + 10R) 30I(120R) Staurosporine, before and after ISL Failed to [17] 
CP-stim abolish 
lx(5I + 10R) 30I(120R) Staurosporine, after CP-stim ISL Abolishes 
Bradykinin 30I(120R) Staurosporine, after CP-stim ISL Abolishes 
Bradykinin 30I(120R) Polymyxin B, 50 min starting 5 ISL Abolishes 
min before CP-stim 
lx(5I + 10R) 30I(180R) Polymyxin B, 5 min after ISL Abolishes [52] 
CP-stim 
Phenylephrine 30I(120R) Polymyxin B, before and after ISL Abolishes [55] 
CP-stim 
Angiotensin II 30I(120R) Polymyxin B, 50 min starting 5 ISL Abolishes [56] 
min before CP-stim 
Rat lx(5I + 10R) 45I(150R) Cheleythrine, after CP-stim ISL Abolishes [53] 
3x(3I + 5R) 90I(240R) Calphostin C, before and after ISL Abolishes [68] 
CP-stim 
Rabbit lx(5I + 10R) 30I(180R) Staurosporine, 5 min after ISL Abolishes [52] 
CP-stim 
lx(5I + 10R) 30I(180R) Polymyxin B, 5 min after ISL Abolishes 
CP-stim 
lx(5I + 10R) 30I(180R) Chelerythrine, 8 min after ISL Abolishes [67] 
CP-stim 
lx(5I + 10R) 30I(180R) Staurosporine, before CP-stim ISL Attenuates [63] 
lx(5I + 10R) 30I(180R) Colchicine, 30 min before ISL Abolishes 
before CP-stim 
Dog 4x(5I + 10R) 60I(240R) H-7 (IV), before, during and ISL Failed to [64] 
after CP-stim abolish 
4x(5I + 10R) 60I(240R) H-7 (IC), before, during and ISL Failed to 
after CP-stim abolish 
4x(5I + 10R) 60I(240R) Polymyxin B, before, during ISL Failed to 
and after CP-stim abolish 
4x(5I + 5R) 90I(360R) Polymyxin B, 5 min before and ISL Abolishes [28] 
during CP-stim 
4x(5I + 5R) 90I(360R) GF109203X, 5 min before and ISL Abolishes 
during CP-stim 
Methoxamine 90I(360R) Polymyxin B, 5 min before and ISL Abolishes 
during CP-stim 
Methoxamine 90I(360R) GF109203X, 5 min before and ISL Abolishes 
during CP-stim 
Pig 2x(10I + 30R) 60I(120R) Staurosporine ISL Failed to [69] 
abolish 
BIS 60I(120R) Bisindolylmaleimide ISL Mimics 
I = ischemia; R = reperfusion; CP = cardioprotective; BIS = bisindolylmaleimide; H-7 = 1-(5-isoquinolinesulfonyl)-2-methylpiperazine; ISL 
= infarct size limitation; FR = functional recovery. 
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Table 2. Protein kinase C activators and myocardial infarct size. 
Prolonged- 
Ischemia Evaluation 
Model Species CP-Stimulus I(R) (min)  (ISL/FR) Result Reference 
Isolated heart Rat SAG 20I(40R) FR Mimics [48] 
Rabbit PMA 30I(18OR) ISL Mimics [52] 
OAG 30I(180R) ISL Mimics 
PMA 30I(120R) ISL Mimics [63] 
In Vivo Rat DOG 45I(150R) ISL Mimics [53] 
Rabbit PMA 30I(180R) ISL Mimics [63] 
Pig PMA None ISL Failed to mimic [69] 
I = ischemia; R = reperfusion; CP = cardioprotective; SAG = 1-stearoyl-2-arachidonoyl glycerol; PMA = phorbol-12-myristate-13-acetate; 
OAG = oleyl acetyl-glycerol; DOG = 1,2-dioctanoyl sn-glycerol; ISL = infarct size limitation; FR = functional recovery. 
Table 3. Protein kinase C translocation/activation and protection by ischemic preconditioning. 
Prolonged- 
CP-Stimulus Ischemia 
Model Species x(I + R) (min) I(R) (min) PKC assay Result Reference 
Isolated heart 
In Vivo 
Rat lx(2I) None Immunohistofluorescence 
Phenylephrine None Immunohistofluorescence 
Dog 4x(5I + 10R) None Fluorescent to binding by 
confocal microscopy 
4x(5I + 10R) None Activity by protein 
phosphorylation 
None 10I Activity by protein 
phosphorylation 
4x(5I + 10R) 10I Activity by protein 
phosphorylation 
PMA None Activity by protein 
phosphorylation 
Dog 4x(5I + 5R) None Activity by protein 
phosphorylation 
Pig lx(10I + 7.5R) None Immunoreactivity on 
Western blot 
lx(10I + 7.5R) None Activity by protein 
phosphorylation 
Pig 2x(10I + 30R) None Activity by protein 
phosphorylation 
PMA None Activity by protein 
phosphorylation 
PKC-5 to sarcolemma, • to [48] 
nucleus, no 4, ~, ~1 
PKC-5 to sarcolemma, ~to 
nucleus, no •, ~, ~1, 
No PKC translocation [64] 
No PKC activation 
PKC activation vs Con 
PKC activation vs Con 
PKC activation 
PKC activation [28] 
PKC-• translocation [58] 
PKC-• translocation 
PKC activation [69] 
PKC activation 
I = ischemia; R = reperfusion; CP = cardioprotective; PMA = phorbol-12-myristate-13-acetate; PKC = protein kinase C 
that in that study the low dose of PMA activated an 
isotype that is protective, while at the higher dose an 
isotype was activated that was damaging [78]. 
Measurements ofprotein kinase 
C-translocation (activation) (Table 3) 
Translocation of protein kinase C from the cytosol to 
the membrane has been investigated employing: 
(1) immunoblot analysis using protein kinase C iso- 
type-specific antibodies of SDS-electrophoretically 
separated subcellular fractions isolated from myocar- 
dial homogenates [44,51,69]; (2) immunohistofluores- 
cence detection (with confocal microscopy) of protein 
kinase C isotypes in sections of myocardial tissue 
[48,64]; (3) assay of total protein kinase C activity in 
subcellular fractions isolated from myocardial homog- 
enates by measurement of Ca 2+- and/or 1,2-DAG- 
dependent 32p incorporation from ~-32p-labelled ATP 
into histone I I I -S or a protein kinase C isoenzyme- 
specific substrate protein such as peptide-e 
[51,54,64,79] or other peptides [28,64]. All three 
methods have their limitations. For instance, in pro- 
tein phosphorylation or immunoreactivity assays, car- 
diac biopsies are usually rapidly frozen in liquid Nz, 
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followed by preparation of particulate fractions from 
the homogenates. It can not be excluded, however, 
that redistribution or (in) activation occurs during iso- 
lation of the subcellular f actions. In the subfractions 
both the basal rate and the maximum rate of histone 
III-S (or other substrate protein) phosphorylation are 
measured in the presence of Ca 2+, PtdSer and 1,2- 
DAG. The results of these measurements only reflect 
the total protein kinase C activities in the subcellular 
fractions. Moreover, histone III-S is a relatively poor 
substrate for some nPKC's (5, e and 0) compared to 
the cPKC's [41]. Therefore, measurements of the rate 
of 32p incorporation i to the synthetic protein kinase 
C-t-specific substrate peptide-e may provide the re- 
quired information about he • isotype [51]. It should 
also be noted that mixed micelles of CaZ+-I,2-DAG - 
PtdSer embedded in Triton-X-100 micelles, used to 
activate protein kinase C in the 3zp incorporation 
assays, only mimic the cellular membrane nviron- 
ment of protein kinase C in the intact cell. It is un- 
known whether myocardium is preconditioned homog- 
enously or heterogeneously. In the latter case, the 
sampling site of the biopsy may pose a restriction. 
Because protein kinase C assayed in subcellular f ac- 
tions isolated from homogenates of whole myocardial 
tissue represents a mixture of activities of myocytes, 
fibroblasts, smooth muscle cells and endothelial cells, 
immunohistofluorescence measurements must there- 
fore be performed to provide information on the cell 
type involved in protein kinase C translocation/activa- 
tion. Measurements of protein kinase C isotype activ- 
ity by immunohistofluorescence must, however, be in- 
terpreted with caution, because the specific antibodies 
are not always capable to distinguish active from inac- 
tive protein kinase C isotypes. 
Weinbrenner t al, using Western blotting, showed 
in rats a rapid translocation of the Ca2+-dependent 
protein kinase C isotype a and the Ca2+-independent 
isotypes (5, • and ~) to the sarcolemma fter brief 
ischemia and increased expression of the Ca 2÷- 
independent protein kinases C-5 and -• in the cytosol 
after prolonged ischemia [24]. Mitchell et al, using im- 
munohistofluorescence, showed in rat hearts that pro- 
tein kinase C-5 translocated from the cytosol to the 
sarcolemma after both brief ischemia and al- 
adrenergic stimulation [48]. Brief ischemia lso caused 
translocation of protein kinase C-• from the cytosol 
to the nuclear egion. Measurements of other protein 
kinase C-isotypes (c~, ~1, ~ and 0) did not provide evi- 
dence for occurrence of translocation after brief is- 
chemia or cq-adrenergic stimulation [48]. These re- 
sults provide the first evidence that (at least in the 
rat) specific protein kinase C isotypes are involved in 
ischemic preconditioning. 
Przyklenk et al used a probe consisting of the pro- 
tein kinase C inhibitor bisindolylmaleimide conjugated 
to fluorescein that selectively binds to active protein 
kinase C and observed no difference in the total 
amount and the cellular distribution of protein kinase 
C fluorescence with preconditioning in dogs [64]. The 
advantage of this method over immunofluorescence is 
that it distinguishes between active and inactive pro- 
tein kinase C. In their study Przyklenk et al also ob- 
tained quantitative information on the changes in the 
amount and subcellular distribution of protein kinase 
C by measuring the rate of 32p incorporation i to the 
threonine group of a protein kinase C-specific peptide, 
which was not further specified [64]. A small rise in 
protein kinase C activity was found in the membrane 
fraction isolated from biopsies obtained after 10 min 
of ischemia compared to those isolated after four se- 
quences of 5 min occlusion-reperfusion or o interven- 
tion [64]. However, no difference in protein kinase 
C activity between matched groups of controls and 
'ischemic preconditioned' ogs could be measured at 
time points comparable to the onset of the long occlu- 
sion or at 10 rain into sustained ischemia [64]. Using 
the same protein kinase C analysis, Vogt et al found 
a modest (10 to 20%) redistribution of protein kinase 
C from the cytosol to the membrane fraction in pig 
hearts subjected to 10 min of ischemia [69]. In con- 
trast to the studies by Przyklenk et al [64], Kitakaze 
et al [28] observed in the same canine model a marked 
translocation ofCa 2÷- and lipid-dependent protein ki- 
nase C activity in cytosol and membrane fractions iso- 
lated from preconditioned pi- as well as endomyocar- 
dium. These authors ascribed their positive findings 
to the time of measurements (5 min after the precondi- 
tioning stimulus against 10 min by Przyklenk et al 
[64]). 
We studied translocation of protein kinase C en- 
zyme activity by 32p incorporation i to histone III-S 
and e-peptide and immunoreactivity of a number of 
protein kinase C isoforms ((~, e, 5 and ~) of cytosolic 
and membrane fractions isolated from biopsies of por- 
cine myocardium preconditioned by a 10-minute coro- 
nary artery occlusion and 7.5-minutes of reperfusion 
[51,80]. Ca 2+ and 1,2-DAG-stimulated protein kinase 
C activity with histone III-S as substrate was higher 
in the cytosolic and particulate fractions isolated from 
the preconditioned myocardium than from the control 
region. Significant Ca2+-independent, 1,2-DAG- 
stimulated phosphorylation f e-peptide was found in 
the cytosolic fractions, but not in the particulate frac- 
tions. However, no significant increase of 1,2-DAG- 
stimulated phosphorylation of e-peptide in the cyto- 
solic fraction from the preconditioned myocardium 
was observed. These were rather unexpected findings 
in view of our protein kinase C-e immunoreactivity 
measurements (see below). The cytosolic and particu- 
late fractions were also examined by immunoblot anal- 
ysis using rabbit polyclonal antibodies specific for pro- 
tein kinase C-(~, -5, -e and -~ isotypes [51]. This 
analysis revealed significant levels of expression of the 
Ca2+-independent isotype protein kinase C-e, the 
abundant presence of protein kinase C-ct, while pro- 
tein kinase C-5 and -~ were barely undetectable. The 
immunoreactivity data also indicate that neither the 
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(Ca 2÷ and 1,2-DAG)-stimulated histone I ILS and pep- 
tide-e kinase activities of the cytosolic nor those of the 
particulate fractions reflect he relative immunoreac- 
tivities in the corresponding fractions. In contrast o 
the ~P-incorporation data, the immunofluorescence 
data suggested that the total amount and subcellular 
distribution of protein kinase C-(~ and -e was not al- 
tered in the preconditioned region compared to the 
non-ischemic region of the left circumflex coronary ar- 
tery. Therefore, by using immunofluorescence w
were unable to detect the occurrence of ischemia- 
induced expression of protein kinase C or ischemia- 
induced translocation ofprotein kinase C from the cy- 
tosolic to the particulate fraction of the protein kinase 
C isotype -~, -8, -e or 4. On the other hand, binding 
proteins, such as myristoylated-alanine-rich-C-kinase- 
substrate (MARCKS) and RACK may determine 
whether activated protein kinase C isotypes translo- 
cate and are providing another mechanism for func- 
tional specificity to specific intracellular locations. 
Thus, in the in vitro phosphorylation assays of the 
subcellular f actions, different amounts of MARCKS- 
or RACK-bound protein kinase C isotypes can alter 
the protein kinase C activity measured [81]. This 
could cause the discrepancy between the activity 
assays and Western blotting. Nevertheless, our re- 
sults on 32p incorporation demonstrate an increase in 
cytosolic and membrane-bound protein kinase C activ- 
ities due to brief ischemia nd supports a role for pro- 
tein kinase C in ischemic preconditioning in pigs [51]. 
target protein(s). Because the time course of weaning 
of the protective ffect of the CPP is roughly known, 
the time course of dephosphorylation/inactivation of 
the target protein could be correlated to the time 
course of weaning of protection. Candidate target pro- 
teins of protein kinase C involved in the CPP are e.g. 
the g~w P channel [13,14] and/or the ecto-5'- 
nucleotidase [28], but experimental evidence for phos- 
phate incorporation i to these proteins or regulating 
proteins is lacking. If the K~T P channel or the ecto-5'- 
nucleotides are target proteins the most likely translo- 
cation site for the protein kinase C isotype(s) involved 
in the CPP is the sarcolemma. 
Protein kinase C is involved in the agonist-receptor 
interaction induced changes in gene expression of 
many cells [25,36,37,41,74,75,83]. Taking into account 
the time required for inducing heat shock/stress pro- 
teins [29,30] the former may only play a role in SWOP. 
Therefore, a transcription factor involved in the regu- 
lation of expression of heat shock/stress proteins 
could be another potential target protein of protein 
kinase C. If true, the nucleus may be the translocation 
site for the protein kinase C isotype(s). 
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Conc lud ing  Remarks  
At present MARCKS is the only endogenous target 
protein for protein kinase C, that has been shown to 
be phosphorylated in preconditioned rabbit myocar- 
dium. However, the former is believed to be an intra- 
cellular location site rather than a protein factor inti- 
mately involved in the protective response [82]. 
Irrespective of the target protein(s) we are dealing 
with, its (their) covalently bound phosphates must be 
relatively stable during the 2 to 3 hours in which the 
cardioprotection is present (CPP). Furthermore, the 
precise time point that protein kinase C is maximally 
translocated (activated) during ischemia or reperfu- 
sion (preconditioning stimulus) is unknown and conse- 
quently also the time point at which the enzyme 
reaches the target proteins for catalyzing their phos- 
phorylation. It is quite feasible that protein kinase C 
is removed from its translocation site or proteolyti- 
cally degraded after it has performed its action and 
thereafter it is no longer detectable by immunoreac- 
tivity or activity measurements. It is therefore man- 
datory to determine the time course of translocation/ 
activation and subsequent relocalization/inactivation 
or proteolytic degradation ofthe protein kinase C iso- 
type and the time course(s) of phosphorylation a d 
dephosphorylation r proteolytic degradation of the 
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